| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRNEPH.2013.104 |
| P698 | PubMed publication ID | 23732458 |
| P50 | author | Vivekanand Jha | Q38800410 |
| P2093 | author name string | Gopesh K Modi | |
| P2860 | cites work | Incorporating societal concerns for fairness in numerical valuations of health programmes | Q33855351 |
| Chronic kidney disease: global dimension and perspectives | Q34347984 | ||
| Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis | Q34660044 | ||
| Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease | Q36943996 | ||
| Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study | Q39599282 | ||
| Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. | Q51166228 | ||
| 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. | Q51174746 | ||
| Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. | Q51960934 | ||
| Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement | Q56880246 | ||
| Accounting for the missing opportunity costs in incremental cost-outcome analysis | Q79296346 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| quality-adjusted life year | Q614165 | ||
| P304 | page(s) | 377-379 | |
| P577 | publication date | 2013-06-04 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD. | |
| P478 | volume | 9 |
Search more.